ANCA-associated vasculitis
The anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAVs) are a
group of disorders involving severe, systemic, small-vessel vasculitis and are characterized …
group of disorders involving severe, systemic, small-vessel vasculitis and are characterized …
Outcomes from studies of antineutrophil cytoplasm antibody associated vasculitis: a systematic review by the European League Against Rheumatism systemic …
C Mukhtyar, O Flossmann, B Hellmich… - Annals of the …, 2008 - ard.bmj.com
Objectives: We undertook a systematic literature review as a background to the European
League Against Rheumatism (EULAR) recommendations for conducting clinical trials in anti …
League Against Rheumatism (EULAR) recommendations for conducting clinical trials in anti …
2018 Update of the EULAR recommendations for the management of large vessel vasculitis
B Hellmich, A Agueda, S Monti, F Buttgereit… - Annals of the …, 2020 - ard.bmj.com
Background Since the publication of the European League Against Rheumatism (EULAR)
recommendations for the management of large vessel vasculitis (LVV) in 2009, several …
recommendations for the management of large vessel vasculitis (LVV) in 2009, several …
Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis
Background Eosinophilic granulomatosis with polyangiitis is an eosinophilic vasculitis.
Mepolizumab, an anti–interleukin-5 monoclonal antibody, reduces blood eosinophil counts …
Mepolizumab, an anti–interleukin-5 monoclonal antibody, reduces blood eosinophil counts …
EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis
In this article, the 2009 European League Against Rheumatism (EULAR) recommendations
for the management of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis …
for the management of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis …
[HTML][HTML] EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update
B Hellmich, B Sanchez-Alamo, JH Schirmer… - Annals of the …, 2024 - ard.bmj.com
Background Since the publication of the EULAR recommendations for the management of
antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) in 2016, several …
antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) in 2016, several …
Mycophenolate mofetil versus cyclophosphamide for remission induction in ANCA-associated vasculitis: a randomised, non-inferiority trial
RB Jones, TF Hiemstra, J Ballarin… - Annals of the …, 2019 - ard.bmj.com
Objectives Cyclophosphamide induction regimens are effective for antineutrophil
cytoplasmic antibody (ANCA)-associated vasculitis (AAV), but are associated with infections …
cytoplasmic antibody (ANCA)-associated vasculitis (AAV), but are associated with infections …
Eosinophilic granulomatosis with polyangiitis (Churg‐Strauss): clinical characteristics and long‐term followup of the 383 patients enrolled in the French Vasculitis …
Objective Earlier studies of eosinophilic granulomatosis with polyangiitis (Churg‐
Strauss)(EGPA), with limited patient numbers and followup durations, demonstrated that …
Strauss)(EGPA), with limited patient numbers and followup durations, demonstrated that …
Modification and validation of the Birmingham Vasculitis Activity Score (version 3)
C Mukhtyar, R Lee, D Brown, D Carruthers… - Annals of the …, 2009 - ard.bmj.com
Background: Comprehensive multisystem clinical assessment using the Birmingham
Vasculitis Activity score (BVAS) is widely used in therapeutic studies of systemic vasculitis …
Vasculitis Activity score (BVAS) is widely used in therapeutic studies of systemic vasculitis …
Диагностические индексы в дерматологии
ВП Адаскевич - 2014 - elibrary.ru
Книга посвящена систематизации количественной оценки дерматологических
заболеваний. Во второе издание вошли зарекомендовавшие себя на практике и …
заболеваний. Во второе издание вошли зарекомендовавшие себя на практике и …